gliclazide has been researched along with rosiglitazone in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (63.16) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chander, R; Chaturvedi, D; Ray, S; Srivastava, AK | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Gomis, R; Jones, NP; Patwardhan, RN; Squatrito, S; Wolffenbuttel, BH | 1 |
| Chow, WH; Davies, C; Jiang, J; Li, GW; Pan, CY; Shi, HL; Sun, XC; Tian, H; Yang, WY; Zhu, XX | 1 |
| Kadioglu, M; Kalyoncu, NI; Kesim, M; Ulku, C; Yaris, E; Yaris, F | 1 |
| Baksi, A; James, RE; Nolan, JJ; Zhou, B | 1 |
| Schumm-Draeger, PM | 1 |
| Whitelaw, D | 1 |
| Choudhury, H; Harisudhan, T; Mullangi, R; Srinivas, NR; Venkatesh, P | 1 |
| Bolusani, H; Evans, LM; Geen, J; Jackson, SK; Khanolkar, MP; Morris, RH; Roberts, AW; Thomas, AW | 1 |
| Alagona, C; Chiavetta, A; Fedele, V; Leotta, C; Lorenti, I; Luca, S; Papa, G; Pezzino, V; Piro, S; Purrello, F; Rabuazzo, AM; Spadaro, L | 1 |
| Gallen, IW; Lumb, AN | 1 |
| Agra, R; Albuquerque, JL; Arahata, C; Arruda, MJ; Canadas, V; Gusmão, A; Montenegro, L; Pontes, L; Silva, LM; Vilar, CF; Vilar, L | 1 |
| Bloomgarden, Z | 1 |
1 review(s) available for gliclazide and rosiglitazone
| Article | Year |
|---|---|
[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus].
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Gliclazide; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors | 2005 |
5 trial(s) available for gliclazide and rosiglitazone
| Article | Year |
|---|---|
Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Fructosamine; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Triglycerides | 2000 |
Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C.
Topics: Adult; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Environmental Exposure; Female; Gliclazide; Glyburide; Glycated Hemoglobin; Hepatitis B; Hepatitis C; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2003 |
Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Male; Middle Aged; Placebos; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2004 |
Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet PPARgamma activation.
Topics: Adult; Aged; Blood Glucose; Blood Platelets; CD40 Ligand; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Male; Middle Aged; Oxidative Stress; Platelet Aggregation; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2008 |
Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs.
Topics: Administration, Oral; Aged; Blood Glucose; Body Mass Index; Carbamates; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pioglitazone; Piperidines; Research Design; Rosiglitazone; Thiazolidinediones | 2008 |
13 other study(ies) available for gliclazide and rosiglitazone
| Article | Year |
|---|---|
Omega-(2-Naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents.
Topics: Alkanes; Alkylation; Amination; Animals; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Metabolism; Male; Molecular Structure; Naphthalenes; PPAR gamma; Rats; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman.
Topics: Adult; Anxiety Disorders; Apgar Score; Atorvastatin; Chronic Disease; Diabetes Complications; Epilepsy; Female; Gliclazide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypoglycemic Agents; Infant, Newborn; Obesity, Morbid; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Pyrroles; Rosiglitazone; Thiazolidinediones | 2004 |
Management of diabetes during Ramadan.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Gliclazide; Humans; Hypoglycemic Agents; Islam; Male; Metformin; Rosiglitazone; Thiazolidinediones | 2005 |
Simultaneous estimation of six anti-diabetic drugs--glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human p
Topics: Carbamates; Chromatography, High Pressure Liquid; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Molecular Structure; Pioglitazone; Piperidines; Reproducibility of Results; Rosiglitazone; Thiazolidinediones | 2006 |
Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Hepatocyte Nuclear Factor 1-alpha; Humans; Hypoglycemic Agents; Middle Aged; Pioglitazone; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2009 |
Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes.
Topics: Adult; Aged; Analysis of Variance; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2010 |
Recent cardiovascular trials: what are the drivers of benefit and adverse effect?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetic Angiopathies; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Rosiglitazone; Thiazolidinediones | 2009 |